GLP-1 Pills Make Weight-Loss Drugs a Consumer Purchase. Staying On Them Is Now the Hard Part

For three years the question about GLP-1 drugs was who could get them. Supply was short, injections listed at more than $1,000 a month, and access ran through an employer’s benefits decision. In 2026 that question is fading. Two once-daily pills, Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, now sell directly to consumers from $149 a month in cash [3][5].

At the same time employers are pulling back. Among Business Group on Health members, coverage of GLP-1s for weight loss fell from 72% to 60% in a year, and no employer surveyed plans to add it for 2027 [11]. The two trends point the same way: GLP-1s are moving from a benefit decision to a consumer purchase.

That changes where programs win or lose. When getting the drug is easy, the hard parts are the ones that come after: staying on it, coping with the side effects, keeping muscle, and what happens when people stop. Those are behavioral problems, and they are measurable.

The two pills, side by side

The trials were not head to head, so the weight loss figures are not a ranking. What the table does show is the shape of the change: a pill that needs no injection and, for Foundayo, no timing rules, at less than half the cash price of the cheapest injection at the starting dose.

Employers expect exactly what that implies. In Business Group on Health’s survey, 87% of employers said they expect an oral GLP-1 to raise demand for the drugs [10].

Access is getting easier. Persistence is not.

The best real-world data on staying on GLP-1s comes from pharmacy claims. Prime Therapeutics followed commercially insured adults with obesity and without diabetes [8]:

• 33% of those who started in 2021 were still on treatment a year later.
• 63% of those who started in early 2024 were, an improvement Prime attributes largely to the end of the 2024 drug shortages.
• Only 8%, about one in twelve, of those who started between January 2021 and March 2022 were still on treatment three years later.

Stopping matters because the effect does not outlast the drug. In the STEP 1 trial extension, people who had lost an average of 17.3% of their body weight on semaglutide regained about two-thirds of it within a year of stopping, and gains in blood pressure, blood sugar and lipids largely reversed with it [9].

The pills remove some reasons people stop, such as needles, fridges and supply. They add one: a daily pill is 365 decisions a year where a weekly injection is 52. No real-world persistence data for either pill exists yet. Anyone who tells you how it will compare is guessing.

Where programs now win or lose

1. The first three months. Gastrointestinal side effects typically cluster around starting and raising the dose, and side effects are a common reason people stop: in Foundayo’s trials, 6 to 10% of participants stopped because of adverse reactions, against 3% on placebo [2]. A program that checks in at each dose step, helps with nausea and eating patterns, and catches early drop-off is working on the period where persistence is decided.

2. Muscle. In the STEP 1 body composition substudy, lean mass made up about two-fifths of the tissue lost, by most calculations [7]. Lean mass is not all muscle, but the direction is clear, and resistance training and protein are the standard countermeasures. A program can see whether strength sessions actually happen from workout data, rather than asking.

3. The off-ramp. Most people will stop at some point, on the evidence above. A program that only supports people while they take the drug hands them back at the moment the weight starts to return. A maintenance phase, built on the activity and sleep habits formed during treatment and watched with the same data, is where the long-term result is decided.

4. Reading wearable data in context. In a 2025 study with WHOOP, people on GLP-1 therapy saw resting heart rate rise by about 3 beats per minute and heart rate variability fall by about 6 milliseconds, with smaller rises in resting heart rate among those who exercised more [12]. A recovery or readiness score built on those signals can drop for reasons that have nothing to do with training or sleep. Products that know a user has started a GLP-1 should say so when they explain a score, rather than telling someone on a new medication that they are poorly recovered.

What it means if you pay for health benefits

If you are an employer or insurer that has stopped or limited coverage, your members have not stopped taking GLP-1s. At $149 to $299 a month, many will buy them anyway, through the makers’ own pharmacies or a telehealth provider [3][5]. You no longer control access, but you still carry the consequences in claims, absence and the regain that follows stopping.

That makes the support around the drug worth more than it was. A program that helps members who are paying for the drug themselves stay on it, keep muscle and land the off-ramp addresses the part of the problem that is still yours, at a fraction of the cost of the drug. We covered how benefits teams are judging those vendors in employers face the biggest health cost rise since 2003.

GLP-1 pills make the drug easier to start and easier to buy without an employer. They do not make it easier to stay on, to keep muscle while on it, or to keep the weight off after stopping, and the evidence says those are where most of the outcome is lost. The programs and products that matter in 2027 will be the ones built for the months after the first prescription.